ALD develops with chronic daily #alcohol consumption (>20 g/d for women, >30 g/d for men) and encompasses reversible #steatosis, #steatohepatitis, #fibrosis, #cirrhosis, and #hepatocellular #carcinoma. 🔗 ja.ma/4eVgvZK
Mads Israelsen
@israelsenm.bsky.social
MD PhD. Hepatology researcher. Odense Liver Research Center. EASL YI Task Force.
📝 JAMA Review: #AlcoholRelatedLiverDisease is the leading cause of #liver-related #mortality and the most common indication for liver #transplant in Europe and the US, with mortality rates rising over the past two decades. 🔗 ja.ma/4eVgvZK
Our work exploring host-microbial co-metabolism of bile acids in patients with alcohol-related liver disease (ALD) has been published in the JHEP Reports: www.sciencedirect.com/science/arti... 🪐 A big thank you to everyone involved, to the GALAXY and MicrobLiver consortia who made this possible! 🙌
Alcohol-related liver disease disrupts bile acid homeostasis and gut microbial bile acid metabolism
Alcohol overuse disrupts liver function and alters gut microbial communities, with alcohol-related liver disease (ALD) causing half of all liver-relat…
sciencedirect.com
This morning, with the talk 'From biomarkers to bedside: Stratified risk assessment in ALD/MetALD and mobile health to close care gaps', @israelsenm.bsky.social (Odense University Hospital) contributed to the session The Road Ahead [...] at #EASLCongress #EASL2026 #MetALD
First randomized trial to show Ozempic reduces alcohol consumption in people seeking treatment for alcohol use disorder. Placebo-controlled, double-blind. Participants with BMI >30 kg/m2. thelancet.com/journals/lan...
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-...
thelancet.com
New research - Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study www.thelancet.com/journals/lan... #LiverSky #MedSky @aleksanderkrag.bsky.social @israelsenm.bsky.social
How should we use PEth in SLD care? 🩸🍺 Our study in @lancetgastrohep.bsky.social (n≈3,000) shows: 🔍 39% of MASLD → MetALD/ALD with PEth ⨻ Triangulating self-report + AUDIT-C + PEth = better classification ⚖️ But 40% get no added value → use selectively www.sciencedirect.com/science/arti...
Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study
Phosphatidylethanol is a direct biomarker of alcohol consumption within the past 1–4 weeks, making it a potential tool in the subclassification of pat…
sciencedirect.com
New Review - Screening for advanced steatotic liver disease www.thelancet.com/journals/lan... #LiverSky #MedSky @aleksanderkrag.bsky.social
Screening for advanced steatotic liver disease
Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...
thelancet.com
🎉Our new Impact Factor is 7.5! We are firmly among the top journals in hepatology👏 Thank you to our authors, reviewers & readers!🙏 #LiverSky @easlnews.bsky.social
New Editorial — Alcohol and health: time for Europe to sober up www.thelancet.com/journals/lan... #alcohol #liversky #medsky
📢Our new Impact Factor is 33.0🎉 🥇Ranking number 1 in the Hepatology field🥇 👏Thanks to the Editorial Team, untiring peer reviewers & very innovative authors❕ #LiverSky @easlnews.bsky.social
✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement. 🗓️ What a fun #workshop at #EASLCongress 2025
🧪 Mads Israelsen (Odense Universitetshospital – Svendborg Sygehus) leads together with Alberto Zanetto the YI #Workshop on How to prepare a #Clinical #Practice #Guideline in Hepatology, offering valuable insights for young investigators. 📅 Presented at the #EASLCongress | #EASL2025
One last time #LIVE from the #EASLStudio: Tot Ziens Amsterdam, Hola Barcelona! 👋 As #EASL2025 draws to a close, Debbie Shawcross and Aleksander Krag reflect on the highlights from Amsterdam and set the stage for #EASL2026 in Barcelona. Thank you for an inspiring #EASLCongress - see you next year!
🤩 Full house at General Session 1 today 🥳 Abstract Session “General #Hepatology”, chaired by Aleksander Krag from Odense University Hospital in Denmark 🇩🇰, featuring a broad range of cutting-edge #LiverResearch 🔬. 📅 Presented at #EASLCongress | #EASL2025 🕥 10:30 – 12:30 h @easlnews.bsky.social
📚 Learning from the best at the EASL Congress: Maja Thiele (OUH) discusses Alcohol-related liver disease as part of The JHEP Reports Symposium: Keys to get your manuscript accepted. 💡 #EASL2025
In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM #MedSky #EndoSky #GastroSky
🚨New paper from us in Journal of Hepatology - Using PEth values on >50,000 persons to predict outcomes. www.sciencedirect.com/science/arti...
Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes
Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion …
sciencedirect.com
APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol" www.nature.com/articles/s41... #Liversky
Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️ Over 60% with MetALD/ALD and 38% with MASLD change subclass. This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐 Link: www.cghjournal.org/article/S154...
Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments
Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...
cghjournal.org
MASLD vs MetALD/ALD is often reduced to ‘alcohol or not’. But alcohol use is not binary—and SLD is a dynamic spectrum where alcohol plays a significant role across phenotypes. Time to rethink the simplistic divide 🧐 @aleksanderkrag.bsky.social @natrevgastrohep.bsky.social
Nature Reviews Gastroenterology & Hepatology@natrevgastrohep.nature.com · 2y ago#liversky #gastrosky #oncsky
Have you secured your spot for #EASLCongress 2025 on 7-10 May? 🌍Join us in Amsterdam or online to transform liver care worldwide! easlcongress.eu/2025-registr... 📜The deadline to submit your late-breaker abstract is TODAY, 17 March! easlcongress.eu/2025-abstrac...
New Review - Neurath, Artis, Becker - The intestinal barrier: a pivotal role in health, inflammation, and cancer www.thelancet.com/journals/lan... #GastroSky #MedSky
We're once again hosting the Human #Microbiome conference at @embl.org, organized by Ami Bhatt, Nicola Segata, Mani Arumugam and Peer Bork! We always have a great lineup of speakers, so register now and think about an abstract to submit (abstract submission deadline in June)
EMBL Events@events.embl.org · 2y ago📣 Explore cutting-edge breakthroughs in microbiome research, from methodological innovations to integrative approaches and personalised therapeutics. Join #EESMicrobiome!🦠 📅 16 – 19 Sep 2025 📍 EMBL Heidelberg and Virtual 📥 Submit your abstract by 24 June ➡️ https://s.embl.org/ees25-08-bl
Journal of Hepatology is now on Bluesky 🌤️ 📢Check our January issue❗️ 🎉Celebrating 40 years of discovery in #liverresearch🎉 🙏Thank you to our authors, editors, reviewers, & readers for supporting us on this incredible journey Full issue here👉https://bit.ly/42en2Kp #LiverSky @easlnews.bsky.social
